1. Home
  2. AIMD vs APVO Comparison

AIMD vs APVO Comparison

Compare AIMD & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIMD
  • APVO
  • Stock Information
  • Founded
  • AIMD 1984
  • APVO 2016
  • Country
  • AIMD United States
  • APVO United States
  • Employees
  • AIMD N/A
  • APVO N/A
  • Industry
  • AIMD Biotechnology: Pharmaceutical Preparations
  • APVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • AIMD Health Care
  • APVO Health Care
  • Exchange
  • AIMD Nasdaq
  • APVO Nasdaq
  • Market Cap
  • AIMD 8.5M
  • APVO 5.4M
  • IPO Year
  • AIMD N/A
  • APVO N/A
  • Fundamental
  • Price
  • AIMD $0.74
  • APVO $3.34
  • Analyst Decision
  • AIMD
  • APVO Strong Buy
  • Analyst Count
  • AIMD 0
  • APVO 1
  • Target Price
  • AIMD N/A
  • APVO $296.00
  • AVG Volume (30 Days)
  • AIMD 379.0K
  • APVO 45.6K
  • Earning Date
  • AIMD 03-07-2025
  • APVO 03-04-2025
  • Dividend Yield
  • AIMD N/A
  • APVO N/A
  • EPS Growth
  • AIMD N/A
  • APVO N/A
  • EPS
  • AIMD N/A
  • APVO N/A
  • Revenue
  • AIMD $40,633.00
  • APVO N/A
  • Revenue This Year
  • AIMD N/A
  • APVO N/A
  • Revenue Next Year
  • AIMD N/A
  • APVO N/A
  • P/E Ratio
  • AIMD N/A
  • APVO N/A
  • Revenue Growth
  • AIMD N/A
  • APVO N/A
  • 52 Week Low
  • AIMD $0.40
  • APVO $3.01
  • 52 Week High
  • AIMD $3.10
  • APVO $399.60
  • Technical
  • Relative Strength Index (RSI)
  • AIMD 59.44
  • APVO 28.65
  • Support Level
  • AIMD $0.57
  • APVO $3.77
  • Resistance Level
  • AIMD $0.77
  • APVO $4.47
  • Average True Range (ATR)
  • AIMD 0.06
  • APVO 0.33
  • MACD
  • AIMD -0.00
  • APVO -0.01
  • Stochastic Oscillator
  • AIMD 68.48
  • APVO 19.64

About AIMD Ainos Inc.

Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: